Join
Live feed
·
PRReleasevia Quantisnow
Akebia Therapeutics Inc. logo

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

ByQuantisnow·Wall Street's wire, on your screen.
AKBA· Akebia Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKBA (Akebia Therapeutics Inc.) and more on Quantisnow.